ATE294594T1 - Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung - Google Patents

Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Info

Publication number
ATE294594T1
ATE294594T1 AT99912502T AT99912502T ATE294594T1 AT E294594 T1 ATE294594 T1 AT E294594T1 AT 99912502 T AT99912502 T AT 99912502T AT 99912502 T AT99912502 T AT 99912502T AT E294594 T1 ATE294594 T1 AT E294594T1
Authority
AT
Austria
Prior art keywords
polynucleotide
composition
polynucleotide composition
lyophilized
cryoprotectant
Prior art date
Application number
AT99912502T
Other languages
English (en)
Inventor
Shankar Musunuri
Patrick P Deluca
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE294594T1 publication Critical patent/ATE294594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99912502T 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung ATE294594T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7808098P 1998-03-13 1998-03-13
PCT/US1999/005547 WO1999045966A1 (en) 1998-03-13 1999-03-12 Polynucleotide composition, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
ATE294594T1 true ATE294594T1 (de) 2005-05-15

Family

ID=22141799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912502T ATE294594T1 (de) 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Country Status (14)

Country Link
US (1) US20080081366A1 (de)
EP (1) EP1061955B1 (de)
JP (1) JP2002506048A (de)
KR (1) KR100625385B1 (de)
CN (1) CN100471522C (de)
AT (1) ATE294594T1 (de)
AU (1) AU765177B2 (de)
BR (1) BR9908754A (de)
CA (1) CA2322232A1 (de)
DE (1) DE69925113T2 (de)
ES (1) ES2239440T3 (de)
IL (1) IL138306A0 (de)
PT (1) PT1061955E (de)
WO (1) WO1999045966A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052875B1 (en) * 1998-05-22 2006-05-30 Sumitomo Pharmaceutical Company, Limited Stable gene preparations
WO2000009086A2 (en) * 1998-08-14 2000-02-24 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
AU783918B2 (en) * 1999-11-19 2005-12-22 Eisai Inc. Continuous-flow method for preparing microparticles
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
AU2003218162B2 (en) 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
AU2003218168A1 (en) * 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
AU2003293196A1 (en) 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US7521187B2 (en) * 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
DE102006038240A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Verfahren zur Herstellung eines Komposits aus Oligo- oder Polynucleotiden und hydrophoben biodegradierbaren Polymeren sowie nach dem Verfahren erhaltenes Komposit
GB0701253D0 (en) * 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
EP1970441A1 (de) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid mit einer Sequenz, die eine Disintegrin-Domäne von Metargidin (RDD) kodiert
JP5579164B2 (ja) 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
HK1209140A1 (en) 2012-07-19 2016-03-24 Zoetis Services Llc Bovine influenza c virus compositions
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
BR112017014090A2 (pt) * 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
CA2995101A1 (en) 2015-08-14 2017-02-23 Zoetis Services Llc Mycoplasma bovis compositions
BR112019009113A2 (pt) 2016-11-04 2019-07-16 Baxalta Incorporated formulações de vírus adenoassociado
KR20210032984A (ko) 2018-07-11 2021-03-25 박스알타 인코퍼레이티드 Aav 조성물
KR20210027493A (ko) * 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
CN110596227B (zh) * 2019-08-08 2021-11-23 河北省食品检验研究院（国家果类及农副加工产品质量监督检验中心、河北省食品安全实验室） 飞行时间质谱即用型斯坦利沙门氏菌定性标准样品的制备方法
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
KR102460006B1 (ko) * 2021-11-22 2022-10-27 주식회사 리엔젠 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물의 동결건조 제조방법 및 이에 따라 제조된 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물
CN119372199B (zh) * 2024-11-19 2026-04-21 郑州安图生物工程股份有限公司 干燥保护剂、干燥方法及核酸质控品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5709076A (en) * 1992-09-14 1998-01-20 Lawlor; Shawn P. Method and apparatus for power generation using rotating ramjet which compresses inlet air and expands exhaust gas against stationary peripheral wall
AU2215995A (en) * 1994-04-07 1995-10-30 Akzo Nobel N.V. Freeze-dried compositions comprising rna
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
JP4386965B2 (ja) * 1996-04-26 2009-12-16 メルク エンド カンパニー インコーポレーテッド Ｄｎａワクチン製剤
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren

Also Published As

Publication number Publication date
PT1061955E (pt) 2005-08-31
KR100625385B1 (ko) 2006-09-18
DE69925113D1 (de) 2005-06-09
IL138306A0 (en) 2001-10-31
EP1061955A1 (de) 2000-12-27
EP1061955B1 (de) 2005-05-04
WO1999045966A1 (en) 1999-09-16
BR9908754A (pt) 2000-11-28
KR20010074441A (ko) 2001-08-04
CA2322232A1 (en) 1999-09-16
AU3086899A (en) 1999-09-27
ES2239440T3 (es) 2005-09-16
DE69925113T2 (de) 2006-01-19
CN1294520A (zh) 2001-05-09
US20080081366A1 (en) 2008-04-03
CN100471522C (zh) 2009-03-25
AU765177B2 (en) 2003-09-11
JP2002506048A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
ATE294594T1 (de) Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung
DE69532137D1 (de) Verbessertes verfahren zur stabilisierung biologischer substanzen während der trocknung und anschliessender lagerung sowie die entsprechenden zusammensetzungen
DE59100581D1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
DK0695408T3 (da) Fremgangsmåde til forbedring af celluloseholdige produkters modstandsevne over for skimmel og råd
DE60003912D1 (de) Verfahren zur herstellung von konditionierungstüchern
ATE433433T1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
NO981106D0 (no) Fremgangsmåte til fremstilling av varmehemmende materiale, samt anvendelse derav
DE59914350D1 (de) Organisches düngemittel mit huminstoffcharakter sowie verfahren zu seiner herstellung und verwendung
ATE294152T1 (de) Substituierte tetrahydro-naphtaline und analoge verbindungen
DE60119711D1 (de) Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
ATE238814T1 (de) Dendrimere fullerenderivate, verfahren zur herstellung und verwendung als neuroprotektiva
DE69937269D1 (de) Bioaktive Peptide, ihre Verwendung und Verfahren zu ihre Herstellung
DE59107488D1 (de) Verfahren zur herstellung wasch- und reinigungsaktiver tensidgranulate
DE69221745D1 (de) Verfahren zur kombinierten Herstellung von organischen Zusammenstellungen und Energie
EP1555033A3 (de) Polynukleotidzusammensetzung, Verfahren zu deren Herstellung und Verwendung
DE69917669D1 (de) Glutaminsäure und glykolsäure verwendendes verfahren zur erhöhung der pflanzenproduktivität
ATE188201T1 (de) Verfahren zur herstellung von oligomethylenharnstoff
MY129550A (en) Production process for natural rubber and natural rubber obtained by the same process
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
ATE195547T1 (de) Antioxidantzusammensetzung und verfahren zu dessen herstellung
ATE286013T1 (de) Verfahren zur herstellung von polyhalogenierten para-trifluoroanilinen
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
ATE213734T1 (de) Verfahren zur herstellung von 1,3- disubstituierten 2-nitroguanidinen
ATE288514T1 (de) Verfahren zur behandlung von wolle enthaltenden geweben, insbesondere kleidungsstücken
DK1214315T5 (da) 1,4-Dihydropyridin-5-carboxylsyreesterderivater og fremgangsmåde til fremstilling af samme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061955

Country of ref document: EP

REN Ceased due to non-payment of the annual fee